Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Monsenso A/S
  6. News
  7. Summary
    MONSO   DK0061277977

MONSENSO A/S

(MONSO)
  Report
Delayed Nasdaq Copenhagen  -  10:26 2022-11-29 am EST
0.4500 DKK   -13.79%
11/10The Momentum Trial : How digital tools can support patient-centered care & shared decision-making
PU
10/25Dipnot : A Research Project to Improve Psychotherapeutic Treatment for People with Depression
PU
10/10Monsenso A/s : World Mental Health Day 2022
PU
SummaryQuotesChartsNewsCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Monsenso participates in new, large innovation project

09/27/2022 | 03:52pm EST

In collaboration with leading researchers and the pharmaceutical industry, the PhaseV innovation project will set new standards for how the effects of treatment can be documented so that patients are offered the right treatment. Patients and healthcare professionals will thus provide data that can help shed light on whether the treatment is working when Monsenso's digital platform is used to support decentralised trials in the project.

Company announcement no. 13-2022

Monsenso (publ.) (Nasdaq First North Growth Market Denmark: Ticker MONSO) is obligated to publish the information in compliance with the EU Market Abuse Regulation.

Copenhagen, 2022.09.27

To date, medical treatments have been tested primarily in long-term, randomised clinical trials to determine treatment effects and side-effects, with limited measurement of long-term effects when treatment is provided in clinical practice.

Often, drug trials take 6-15 years before a new drug can be released on the market, and 80 percent of trials fail to recruit and retain a sufficient number of patients in the trials within the set timeframe. This means that the benefits for patients and healthcare systems are often delayed. However, with digital developments, it is possible for clinics, hospitals, and patients alike to play a more active role in documenting the impact of treatments.

The new PhaseV (Phase five) innovation project, in which Innovation Fund Denmark is investing DKK 24 million (of which DKK 8,3 million goes to Monsenso), aims to develop and validate a scalable digital platform for efficient, decentralised patient recruitment, patient data collection and study execution. This is done by engaging patients and clinicians in the monitoring of treatment effects over longer periods of time based on patients' own feedback, digital biomarkers from smartphones and wearables, as well as registry data.

- With this project, we want to show that it is possible to engage and motivate patients and healthcare professionals to collect continuous data from patients over time. PhaseV will set new standards for how the efficacy and safety of new treatments can be documented in a scalable way in the future, so that patients are offered the right treatment, says Thomas Lethenborg, CEO of Monsenso.

Country Manager for Novartis in Denmark, Peter Drøidal, also sees great potential in the PhaseV project: - The healthcare system lacks resources and therefore we all need to think in new ways. This project's combination of public and private partners offers unique opportunities to develop new digital solutions that can help improve patient care and free up personnel time.

Severe obesity, urticaria and diabetic foot ulcers

The PhaseV project will develop a platform with three apps to collect data on patients with severe obesity, diabetic foot ulcers and urticaria - all of which are costly chronic conditions. For example, annual treatment costs for severe obesity alone are estimated to exceed DKK 15 billion for Danish municipalities and regions.

- More than 800,000 Danes live with severe obesity, and associated diseases are very common. As severe obesity causes both direct and indirect costs to society, there is a significant need for good and well-documented weight loss treatments, says Jens Meldgaard Bruun, clinical professor at Aarhus University and Steno Diabetes Center Aarhus and part of PhaseV.

Urticaria affects 15-20 percent of the population, and in about 1 percent it occurs chronically and causes a severely reduced quality of life.

- Thorough monitoring and efficient data collection on symptom development are crucial for correct and effective future treatment, says Simon Francis Thomsen, Professor and Chief Physician at Bispebjerg Hospital.

22.000 Danes live with diabetic foot ulcers and treatment costs society more than DKK 5 billion annually.

- For a patient with diabetes, a foot ulcer can become critical within days, and in exceptional cases amputation may be necessary. Hence, time is of the essence, and we want to prevent serious complications," says Klaus Kirketerp-Møller, senior physician at Bispebjerg Hospital and Steno Diabetes Center Copenhagen.

The PhaseV project is expected to bring value to patients, regions, and municipalities, as well as to the institutions and companies involved.

Attractive new market opportunity for Monsenso

We are further developing Monsenso's digital health platform to improve the support of decentralised trials across chronic conditions, where behaviour and ongoing follow-up play a major role in patients' quality of life. We see both the development work and the partnerships as very interesting for Monsenso, because it opens up a new, attractive market opportunity, says the CEO of Monsenso, Thomas Lethenborg.

The consortium behind the project, which is supported by the Innovation Fund, includes Novo Nordisk, Novartis, Aarhus University, the Research Unit for General Practice, Aarhus Municipality, Bispebjerg Hospital, Danish Technological Institute, Danish Life Science Cluster, Steno Diabetes Center Aarhus, Copenhagen Institute for Future Studies and Monsenso.

Financial expectations

The project does not change Monsenso's financial expectations for 2022 but is expected to contribute to increased growth in 2023 and beyond.

Facts
Innovation Fund investment: DKK 24.3 million (of which DKK 8.3 million is for Monsenso).
Total project budget: DKK 48.2 million.
Duration: 3 years
Official title: PhaseV

Further information: 

Monsenso:

CEO
Thomas Lethenborg
Tel. +45 21 29 88 27
E-mail: lethenborg@monsenso.com 

Chairman of the board
Peter Mørch Eriksen
Tel. +45 29 00 35
E-mail: petermorcheriksen@outlook.com

Certified Adviser:

Norden CEF A/S
John Norden
Tel. +45 20 72 02 00
E-mail: jn@nordencef.dk



About Monsenso

Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. We collaborate with health and social care, pharmaceuticals and leading researcher worldwide in our endevaours to deliver solutions that fit into the life of patients and health care professionals. To learn more visit  www.monsenso.com

Attachments

  • Download announcement as PDF.pdf
  • Patient with smartphone.jpg
  • Clinician with clinical web portal.jpg

© Ritzau Denmark, source Ritzau English Regulatory Releases

Stocks mentioned in the article
ChangeLast1st jan.
MONSENSO A/S -13.79% 0.45 Delayed Quote.-56.43%
NOVARTIS AG 0.02% 83.3 Delayed Quote.3.74%
All news about MONSENSO A/S
11/10The Momentum Trial : How digital tools can support patient-centered care & shared decision..
PU
10/25Dipnot : A Research Project to Improve Psychotherapeutic Treatment for People with Depress..
PU
10/10Monsenso A/s : World Mental Health Day 2022
PU
09/28Monsenso A/s : Patients will help document treatment efficacy in innovative, decentralised..
PU
09/27Monsenso participates in new, large innovation project
AQ
09/27Monsenso A/S Participates in New, Large Innovation Project
CI
09/19Capital increase in Monsenso as a result of warrants exercising
AQ
09/05Monsenso A/s : Digitalization could help tackle the issue of lacking resources in mental h..
PU
08/31Monsenso A/s : H1 Report 2022
PU
08/31Monsenso presents H1 2022 report
AQ
More news
Financials
Sales 2021 7,14 M 0,99 M 0,99 M
Net income 2021 -8,15 M -1,13 M -1,13 M
Net cash 2021 7,77 M 1,08 M 1,08 M
P/E ratio 2021 -2,00x
Yield 2021 -
Capitalization 11,5 M 1,61 M 1,61 M
EV / Sales 2020 16,6x
EV / Sales 2021 2,80x
Nbr of Employees 14
Free-Float 50,8%
Chart MONSENSO A/S
Duration : Period :
Monsenso A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MONSENSO A/S
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Managers and Directors
Thomas Lethenborg Chief Executive Officer
Robert H°jer Chief Financial Officer
Peter Morch Eriksen Chairman
Mads Maersk Frost Chief Information Security Officer
Morten H÷gholm Pedersen Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
MONSENSO A/S-56.43%2
ACCENTURE PLC-29.90%183 101
TATA CONSULTANCY SERVICES LTD.-9.18%152 148
INTERNATIONAL BUSINESS MACHINES CORPORATION9.60%132 165
AUTOMATIC DATA PROCESSING, INC.4.25%107 162
INFOSYS LIMITED-14.00%83 406